dalteparin has been researched along with Osteolysis in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, RE | 1 |
| Jones, JC | 1 |
| Tometsko, M | 1 |
| Blake, ML | 1 |
| Dougall, WC | 1 |
1 other study available for dalteparin and Osteolysis
| Article | Year |
|---|---|
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Topics: Animals; Anticoagulants; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Enoxaparin; Female; Humans; | 2014 |